Next report date
Report period
Q1 2024
EPS estimate
−0.64USD
Revenue estimate
—
−432.84 MUSD
87.00 M
Om Cerevel Therapeutics Holdings, Inc.
Sektor
Bransch
VD
Ronald C. Renaud
Webbplats
Huvudkvarter
Cambridge
Employees (FY)
334
Grundat
2018
FIGI
BBG00VCYVLH4
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
